Eikon Therapeutics presented updated clinical data at the 2026 ASCO meeting showing encouraging results for its EIK1001 drug in first-line treatment of stage 4 non-small cell lung cancer (NSCLC), with a 63.1% response rate and good tolerability. The company also reported positive safety and efficacy data for EIK1003, a PARP1 inhibitor, both as monotherapy and combined with paclitaxel in advanced solid tumors. These results support continued development of these therapies, which aim to improve cancer treatment outcomes. Eikon plans further trials and data releases in 2026 and beyond.
BNB surged 7.9% in 24 hours, breaking above the key 680 USDT resistance level, which may now act as support. This sharp move reflects renewed buyer interest and possibly short liquidations, amid broader positive altcoin sentiment. Traders will watch ...
Precigen's PAPZIMEOS, the first FDA-approved therapy for recurrent respiratory papillomatosis (RRP), demonstrated durable complete responses in 83% of patients over at least 36 months without additional treatment. Five patients maintained responses b...
Whitehawk Therapeutics announced data showing SEZ6 protein is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors, exceeding other known targets. This supports their development of HWK-206, a next-generation antibody dru...
BioNTech and Bristol Myers Squibb announced encouraging interim Phase 2 results for pumitamig, a PD-L1xVEGF-A bispecific immunomodulator, combined with chemotherapy in untreated advanced non-small cell lung cancer (NSCLC). The ROSETTA Lung-02 trial s...
Computer engineer CharuSan argues XRP's potential $300 price is driven by integration into global banking infrastructure, not retail speculation. After regulatory clarity, XRP could be adopted system-wide via platforms like Volante Technologies, enab...
